Residents and Fellows Research in Progress
Sunday, November 12, 2023
12:45 PM–02:15 PM
Abstract
Introduction: Metformin, a commonly prescribed oral hypoglycemic agent, has been shown to lower ischemic stroke events in diabetes patients in pre-clinical and clinical studies. Before 2016, due to the safety concerns of metformin in patients with kidney disease, the effectiveness of metformin on clinical studies was limited in those populations.
Research Question or Hypothesis: Is the treatment with metformin associated with a lower risk of ischemic stroke in patients with diabetes who have chronic kidney disease?
Study Design: This is a retrospective cohort study of adult patients with diabetes and chronic kidney disease who continued treatment with metformin or other hypoglycemic agents without metformin.
Methods: This study included all adult patients (ages 18-89) with type 2 diabetes in large Cerner data base from 2007 through 2017. Outcomes evaluated were ischemic stroke rate during study periods.
Results: Of 28,121 metformin users and 14,758 no metformin users, there were 5% of ischemic stroke events with no metformin users and 4.9% of events with metformin users. The risk for ischemic stroke event was 0.98 (95% CI 0.90 – 1.07; p = 0.7) among metformin users compared with no metformin users. The cumulative probability of ischemic stroke for patients in metformin group vs no metformin group showed no difference.
Conclusion: Our results show that persistent use of metformin was not associated with a decreased risk of ischemic stroke events in diabetic patients with chronic kidney disease.
Presenting Author
Soon Yang Pharm.D.,BCPSTTUHSC
Authors
Charles F. Seifert Pharm.D. FCCP. BCPS
Chip Shaw Ed.D., MPH
Texas Tech University Health Sciences Center